에 대한 최신 뉴스 BioAtla (NASDAQ:BCAB) 주식

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Asia

Equities

News

Global

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.

&#39;빅쇼트&#39; 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

BioAtla Inc

The company announced partnership with BITMAIN to host next-generation ASIC miner with purchase option to reach 20 EH/s of self-mining

Hut 8 Operations Update For September 2024: Reports 19.5 EH/s And 762 MW Under Management In Mining With Path To 33.5 EH/s

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to total $66.0 million, assuming the underwriters do not exercise their option to purchase additional ADSs.&nbsp;

IPOs

BingEx Prices IPO Of 4M American Depositary Shares At $16.50 Per ADS; To Begin Trading On Nasdaq Stock Market Under Symbol 'FLX'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Price Target

Reiteration

Analyst Ratings

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

The results of this clinical trial are unrelated to Travelan and do not impact Immuron's plans to hold an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) with a view to initiating Phase 3 clinical trial(s) of Travelan in 2H 2025. Nor does this NMRC trial impact on Immuron's commercialization strategy for Travelan. This commercialization strategy also includes the results of the Uniformed Services University clinical study (n=866) of Travelan which is 85% recruited with topline results anticipated in April 2025.

Biotech

Health Care

General

IMRN

Following A Discussion With The US Naval Medical Research Command (NMRC), Immuron Announced That The NMRC Has Completed The Interim Analysis For The Clinical Evaluation Of A New Oral Therapeutic Targeting Campylobacter And Enterotoxigenic Escherichia Coli

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $45 price target.

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) with a Buy and raises the price target from $9 to $11.

ETON

HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $11

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $65 price target.

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target

Traders are cautiously optimistic ahead of the all-important payrolls report, with the index futures narrowly mixed in early Friday. The <a href="https://www.benzinga.com/news/24/10/41177060/port-strike-ends-workers-return-to-work-friday">suspension of the Longshoremen&#8217;s strike</a> removes one of the overhangs even as the Middle East tensions rage unabated. The September job gains could have a big impact on the near-term direction of the market.
&#8220;Payroll data will be closely watched as the sentiment is now that the Fed has become less focused on inflation and more on employment,&#8221; said fund manager Louis Navellier. A BofA note highlighted that the S&amp;P 500 futures have been more reactive to non-farm payroll data than any other economic data in recent years, a screenshot of the note shared by a financial writer on X showed.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.14%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.07%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.05%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.22%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 0.16% to $568.75 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) moved 0.32% higher to $483.14, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks showed nervousness throughout Thursday&#8217;s session before closing lower, with geopolitical tensions, the dockworkers&#8217; strike and mixed economic data weighing down on sentiment. While a bigger-than-expected increase in jobless claims stirred anxiety about the monthly jobs data, the Institute for Supply Management&#8217;s stronger-than-expected service sector purchasing managers&#8217; index tempered expectations concerning a bigger cut.
The Nasdaq Composite oscillated back and forth in the morning session but languished mostly below the unchanged line in the afternoon before ending marginally lower. This is despite IT and communication services posting moderate gains. The broader S&amp;P 500 Index traded mostly in the red and ended modestly lower, with consumer discretionary, consumer staple, healthcare, material and real estate stocks dragging the index lower. On the other hand, energy stocks posted solid gains. The index settled at a two-week low. 
The 30-stock Dow Jones Industrial Average underperformed as it settled down 0.44% at a one-week low.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.04%</td>
<td>17,918.47</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.17%</td>
<td>5,699.94</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.44%</td>
<td>42,011.59</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.09%</td>
<td>2,195.01</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Comerica Chief Economist Bill Adams said he expects the Fed to cut rates by 25 basis points in November, December, January and March and then move toward quarterly rate cuts for the rest of the next year. The economist noted that inflation is slowing to near the Fed&#8217;s 2% target, largely due to lower energy prices. Core inflation, though higher than the headline inflation, could slow due to downward pressure on durable goods and used autos persist and a slower increase in housing costs, he said.
Adams sees the Fed funds rate to be in the range of 3%-3.25% by the end of 2025. That said, the economist does not rule out a faster pace of rate cuts if the economy weakens materially, or a slower rate cut if the large deficit or wars in oil-exporting regions cause inflation to rebound.
Navellier weighed in on the near-term trajectory of the market in a note sent to clients on Thursday. &#8220;Funds flows into equities are likely to remain positive, at least until there is a sustained pullback, which hasn&#8217;t happened since &#8217;22,&#8221; he said.
The fund manager noted that the AI theme got a boost after OpenAI&#8217;s new funding round, which raised $6.6 billion from a long list of well-known investors, valuing the company at $157 billion. Also, Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang&#8217;s comments that demand for the company&#8217;s new Blackwell chips is &#8220;insane,&#8221; is a positive for the sector, he said.
 &#8220;AI adoption remains one of the fastest-growing new technologies ever and continues to promise big gains in productivity, though the timing of meaningful cash flow gains still remains uncertain,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures-on-thinkorswim">How To Trade Futures</a>
Upcoming Economic Data:
<ul>
<li>The Bureau of Labor Statistics is due to release its September non-farm payrolls report at 8:30 a.m. EDT. Economists, on average, expect job gains of 150,000, up from the 142,000 rate in August. The jobless claims are expected to stay put at 4.2% and the average hourly wages may have risen at a steady annual pace of 3.8%.</li>
<li>New York Fed President John Williams is scheduled to give opening remarks at the conference &#8220;The Future of New York City: Focus on Jobs,&#8221; at 9 a.m. EDT.</li>
<li>Chicago Fed President Austan Goolsbee will make a TV appearance at 10 a.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) plunged over 37% after reports said the low-cost carrier is exploring Chapter 11 bankruptcy filing following its failed attempt to merge with JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>). JetBlue climbed over 5%.</li>
<li>Apogee Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) is scheduled to <a href="https://www.benzinga.com/calendars/earnings">announce its quarterly results before the market opens.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures added to their 5%+ gains from Thursday and traded above $74.50, and gold futures traded flat under their all-time high. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed over 1% ahead of the jobs data. The yield on the 10-year Treasury note remained unchanged at 3.85%.
The Asian markets were mixed, with Japan ending modestly higher, and Hong Kong and a few other majors advancing. On the other hand, the Indian, Australian, Malaysian, Indonesian, and Taiwanese markets retreated. The Chinese market continued to remain closed for a weeklong holiday.
In Europe, sentiment is modestly positive in early trading, although the U.K. market is retreating.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41179608/mark-zuckerberg-bulldozes-past-jeff-bezos-to-become-worlds-2nd-richest-person-as-meta-stock-soar">Mark Zuckerberg Bulldozes Past Jeff Bezos To Become World&#8217;s 2nd Richest Person As Meta Stock Soars: Is Musk&#8217;s Top Spot In Jeopardy?</a></li>
</ul>
Image Created By Midjourney

Earnings

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Movers

$BTC

APOG

JBLU

NVDA

SAVE

US Stocks On Edge As Traders Brace For Crucial Jobs Report: Why This Fund Manager Says AI Stocks Just Received Big Boost

Guidance

Apogee Enterprises Raised FY25 Adj. EPS To $4.90-$5.20 From $4.65-$5.00 Vs. Cons. $4.82

Needham analyst Joshua Reilly reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Buy and maintains $25 price target.

JAMF

Needham Reiterates Buy on Jamf Holding, Maintains $25 Price Target

Apogee Enterprises Reaffirmed FY25 Outlook For Net Sales To Decline 4% to 7%

Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) reported quarterly earnings of $1.44 per share which beat the analyst consensus estimate of $1.23 by 17.07 percent. The company reported quarterly sales of $342.440 million which beat the analyst consensus estimate of $335.289 million by 2.13 percent. This is a 3.18 percent decrease over sales of $353.670 million the same period last year.

Earnings Beats

Apogee Enterprises Q2 2025 Adj. EPS $1.44 Beats $1.23 Estimate, Sales $342.440M Beat $335.289M Estimate

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly begun inviting <a href="https://www.benzinga.com/topic/tesla-cybertruck">Cybertruck</a> reservation holders to configure their cheaper non-foundation series version of the vehicle.
What Happened: The news was first flagged on social media platform X by Tesla enthusiast Sawyer Merritt. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Tesla has officially begun inviting people to order the less expensive non-Foundation Series Cybertrucks! It starts at $79,990. The $99,990 ti-motor Cyberbeast is also now available to order. Production of cheaper Cybertrucks is finally about to start! <a href="https://t.co/mTFUbZu1MK">pic.twitter.com/mTFUbZu1MK</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1842049199145205957?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The foundation series of the Cybertruck refers to the limited-edition version of the stainless steel truck with exclusive badges and premium accessories being manufactured by the company for the initial months of starting deliveries. The foundation series Cybertruck starts at $99,990 for the base version. 
The non-foundation series Cybertruck, though less exclusive, will be cheaper. The base version of the non-foundation series Cybertruck starts at $79,990 with the higher-end Cyberbeast variant starting at $99,990. 
The invites to reservation holders imply that Tesla might soon start production of the non-foundation series version. The company did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters: Tesla started delivering the Cybertruck in November 2023.
During Tesla's annual shareholder meeting in early June, Tesla CEO Elon Musk said that the company has touched a weekly production record of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck" target="_blank" rel="noreferrer noopener">1,300 Cybertrucks</a>. The company is now ramping production further to touch 2,500 units per week by the end of the year to deliver 250,000 Cybertrucks a year starting in 2025.
Cybertruck&nbsp;<a href="https://www.benzinga.com/news/24/07/39876213/tesla-confirms-it-aims-to-start-selling-cybertruck-in-canada-this-year-pre-orders-open-for-150" target="_blank" rel="noreferrer noopener">production is on track</a>&nbsp;to achieve profitability by the end of the year, the company said during its second-quarter earnings in July.
In the three months through the end of September, Tesla delivered 22,915 units of the Model X, Model S, and Cybertruck together. The company doesn&#8217;t provide a Model-wise breakdown of deliveries. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41135581/tesla-discontinues-cheapest-model-3-variant-entry-level-trim-now-starts-at-42-490" target="_blank" rel="noreferrer noopener">Tesla Discontinues Cheapest Model 3 Variant: Entry Level Trim Now Starts At $42,490</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Reportedly Starts Inviting Reservation Holders To Order More Affordable Non-Foundation Series Cybertruck

WIIM

RIVN

Rivian shares are trading lower after the company lowered its annual production guidance due to supply shortage of shared component on the R1 and RCV platforms.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $73 price target.

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target

Masayoshi Son, CEO of SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), has forecasted the <a href="https://www.benzinga.com/markets/24/09/40836225/human-like-reasoning-strawberry-ahead-aggressive-nvidia-buying-hotter-inflation-data">advent of artificial superintelligence</a> within the next ten years. This revelation was shared during the SoftBank World 2024 conference.
What Happened: Son, Japan&#8217;s second wealthiest individual, commended OpenAI for its recent technological strides. He specifically mentioned the new GPT-o1 models, codenamed &#8220;Strawberry,&#8221; which he believes have developed reasoning capabilities, <a href="https://observer.com/2024/10/softbank-masayoshi-son-ai-openai-investment/">reported</a> the Observer on Friday. 
"This technology will evolve to a point&nbsp;where your happiness will be its greatest reward," said Son. He claimed that ASI, which would be 10,000 times more powerful than human intelligence, could be achieved within a decade.
Son envisions a future where AI can perform everyday tasks, such as grocery shopping and investment management, ultimately enhancing human happiness. His optimistic outlook is consistent with his history of making bold tech investments.
Looking forward, Son anticipates the achievement of artificial general intelligence, which matches human intelligence, within two to three years. 
He also predicts artificial superintelligence, surpassing human capabilities, within a decade. SoftBank&#8217;s AI strategy is centered around ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), a U.K.-based chip designer, with plans to expand into AI chips, data centers, and industrial robots.
See Also: <a href="https://www.benzinga.com/news/24/09/41020589/tech-youtuber-mkbhd-responds-after-facing-massive-backlash-over-his-new-12-a-month-wallpaper-app?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tech YouTuber MKBHD Responds After Facing Massive Backlash Over His New $12 A Month Wallpaper App</a>
Why It Matters: Son&#8217;s prediction comes amid <a href="https://www.benzinga.com/markets/24/09/40836225/human-like-reasoning-strawberry-ahead-aggressive-nvidia-buying-hotter-inflation-data">growing interest</a> in A.I. advancements, particularly with OpenAI&#8217;s &#8220;Strawberry&#8221; models. These models are noted for their human-like reasoning capabilities, which could revolutionize various industries.
However, <a href="https://www.benzinga.com/news/24/08/40387488/masayoshi-sons-plans-to-rival-nvidia-with-softbanks-own-ai-chip-production-hit-a-roadblock-as-intel">SoftBank&#8217;s ambitions</a> to rival NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in A.I. chip production reportedly faced setbacks when talks with Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) fell through. Despite this, SoftBank is exploring partnerships with other manufacturers like Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Additionally, Son&#8217;s focus on AI aligns with Sam Altman&#8216;s commitment to <a href="https://www.benzinga.com/news/24/05/38608040/openais-sam-altman-says-were-making-agi-and-it-will-be-worth-it-dont-care-if-we-burn-500m-or-50b">developing artificial general intelligence</a>, regardless of the financial cost. This shared vision underscores the significant investments and strategic shifts occurring in the A.I. sector.
Interestingly, SoftBank&#8217;s past decision to sell its Nvidia shares in 2019 resulted in a missed opportunity, as those shares would <a href="https://www.benzinga.com/general/24/06/39489510/the-150-billion-opportunity-softbank-lost-by-selling-nvidia-shares-too-soon">now be approximately worth over $150 billion</a>. This highlights the high stakes and rapid evolution of the AI and tech investment landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41087674/openais-searchgpt-set-to-disrupt-googles-search-empire-as-former-engineer-sounds-alarm-on-deteriorat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">OpenAI&#8217;s SearchGPT Set To Disrupt Google&#8217;s Search Empire As Former Engineer Sounds Alarm On Deteriorating User Experience Amid Rising Competition</a></li>
</ul>
Image Via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

INTC

SFTBF

SFTBY

SoftBank's Masayoshi Son Predicts Artificial Superintelligence Within A Decade After Testing OpenAI's 'Strawberry' Models

The company is also reaffirming its annual delivery&nbsp;outlook&nbsp;of low single digit growth as compared to 2023, which it expects to be in a range of 50,500 to 52,000 vehicles.
Rivian is experiencing a production disruption due to a shortage of a shared component on the R1 and RCV platforms. This supply shortage impact began in&nbsp;Q3&nbsp;of this year, has become more acute in recent weeks and continues.

Rivian Revises Annual Production Guidance To Be 47,000 - 49,000 Vehicles (Prior 57,000), Citing Supply Shortage

Wolfe Research analyst Bill Carcache upgrades M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Peer Perform to Outperform and announces $210 price target.

Upgrades

Wolfe Research Upgrades M&T Bank to Outperform, Announces $210 Price Target

EXAS

Exact Sciences Says FDA Approves Exact Sciences' Cologuard Plus Test, Setting New Benchmark In Non-Invasive Colorectal Cancer Screening, Company Expects To Launch Cologuard Plus Test With Medicare Coverage And Guideline Inclusion In 2025

Rivian Reports Q3 Production Of 13,157 Vehicles At Its Manufacturing Facility In Normal, Illinois and Delivery Of 10,018 Vehicles

Investors are constantly on the hunt for stocks that offer solid returns. However, finding these stocks can be challenging and sometimes expensive....

These 2 "Strong Buy" Penny Stocks Are Poised for a Big Rally, Say Analysts

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioAtla (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcab-stock-quote/">BCAB</a>) just reported results for the second quarter of 2024.<ul><li>BioAtla reported earnings per share of -44 cents. This met the analyst estimate for EPS of -44 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bcab-stock-earnings-bioatla-for-q2-of-2024/">BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024

BioAtla GAAP EPS of -$0.44 in-line

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla (BCAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Secur...

Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential

Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on BioAtla (BCAB – Research Report). The associated price target was raised to $13.00...

Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $5.00. Reni Benj...

Buy Rating Affirmed for BioAtla on Strong Clinical Data and Solid Financial Positioning

BioAtla out-licenses BA3362 to Context Therapeutics

Analyst Justin Zelin of BTIG maintained a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $13.00. Justin Zelin has gi...

Buy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical Catalysts

CNTX

CRMD

PHYS

SBLK

Press Releases

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Adicet Bio

Anixa Biosciences

Annovis Bio

aTyr Pharma

Benitec Biopharma

Coherus BioSciences

Coya Therapeutics

Cardiff Oncology

CervoMed

Elutia

I-MAB

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Invivyd

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Seres Therapeutics

Nuvectis Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Puma Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Regulus Therapeutics

Skye Bioscience

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Verastem

X4 Pharmaceuticals

JMP Securities

HC Wainwright & Co.

JP Morgan

EF Hutton

BTIG

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.
어떤 일이 (What Happened): 사라토가에 본사를 두고 버리가 운영하는 사이언 에셋 매니지먼트(Scion Asset Management)는 수요일 미국 증권거래위원회(SEC)에 최신 13F 보고서를 제출하여 투자 전략의 주목할만한 변화를 밝혔다.
주요 포인트들은 다음과 같다:
<ol>
<li>알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)가 1위 자리를 차지함: 중국의 전자상거래 대기업인 알리바바는 155,000주로 구성된 약 1,116만 달러의 가치를 지닌 사이언의 최대 보유 기업이 되었다.</li>
<li>기술 초점: 이 포트폴리오는 중국 기술 기업들에 대한 지속적인 관심을 보여준다. 이에는 75,000주로 약 649만 달러의 가치를 형성하는 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)와 25만 주로 646만 달러의 가치를 형성하는 징동닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 큰 비중이 포함되어 있다.</li>
<li>헬스케어 및 핀테크: 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)는 각각 729만 달러와 734만 달러 상당의 상당한 투자를 보여준다.</li>
<li>부동산 노출: 허드슨 퍼시픽 프로퍼티즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>)는 550만 달러 상당의 주식 110만 주를 보유한 중요한 부동산 회사로 두각을 나타낸다.</li>
<li>바이오테크 신생기업: 임상 단계의 바이오제약 회사인 바이오아틀라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>)는 포트폴리오에서 작지만 주목할만한 위치를 나타낸다.</li>
</ol>
기타 주목할만한 보유 자산으로는 더 리얼리얼(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), 올라플렉스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), 그리고 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>)가 있다.
중요성 (Why It Matters): 이 최신 서류는 버리의 현재 시장 전망에 대한 통찰력을 제공하며 중국 기술 기업, 미국 의료, 핀테크 및 엄선된 부동산 기회에 대한 상당한 투자를 통한 다양한 접근 방식을 제안한다.
지난 5월 버리는 <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">금 및 신재생 에너지</a>에 대한 막대한 투자로 헤드라인을 장식했으며 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 및 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)에서 포지션을 청산했다. 이 전환점은 실물 상품과 지속 가능한 에너지원에 초점을 맞추었음을 나타낸다.
관련해서, <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">최근의 설문 조사</a>에서는 투자자들이 일론 머스크, 워런 버핏, Burry 자신과 같은 최고 인물들로부터 조언을 구하는 방법을 강조하여 투자 커뮤니티에서 그의 영향력을 강조한다.
Michael Burry illustration by Gonzalo Lanzilotta for
면책 조항: 본 콘텐츠는 인공지능 도구의 도움을 받아 제작되었으며, Benzinga 편집자들에 의해 검토되고 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

'빅쇼트' 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

Comments

BioAtla

뉴스

에 대한 최신 뉴스 BioAtla (NASDAQ:BCAB) 주식

목요일, 8월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌